Many injectable therapies of the glucagon-like peptide 1 (GLP-1) receptor agonist (RA) class (including semaglutide, dulaglutide, exenatide, liraglutide, and lixisenatide) have also been developed and approved for use in Japan [10,11,12,13,14,15,16,17]
As more plaintiffs file lawsuits, Rybelsus plays an increasingly significant role in the multidistrict litigation against Novo Nordisk
Off-Label Use: What Clinicians Should Consider Despite the absence of an approved indication, some pediatric obesity specialists have reported considering off-label GLP-1 receptor agonist use in select children aged 10 to 11 with severe obesity (BMI at or above the 120th percent of the 95th percentile) and weight-related comorbidities such as type 2 diabetes, obstructive sleep apnea, or nonalcoholic steatohepatitis
Once opened, the effectiveness window shortens, and the medication should be used according to your healthcare providers instructions
Many patients lose 13 kg in the first four weeks, though some see less